Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) in the 9p21 gene desert associated with coronary artery disease (CAD) 1-4 and type 2 diabetes [5] [6] [7] . Despite evidence for a role of the associated interval in neighbouring gene regulation [8] [9] [10] , the biological underpinnings of these genetic associations with CAD or type 2 diabetes have not yet been explained. Here we identify 33 enhancers in 9p21; the interval is the second densest gene desert for predicted enhancers and six times denser than the whole genome (P , 6.55 3 10 233 ). The CAD risk alleles of SNPs rs10811656 and rs10757278 are located in one of these enhancers and disrupt a binding site for STAT1. Lymphoblastoid cell lines homozygous for the CAD risk haplotype show no binding of STAT1, and in lymphoblastoid cell lines homozygous for the CAD non-risk haplotype, binding of STAT1 inhibits CDKN2BAS (also known as CDKN2B-AS1) expression, which is reversed by short interfering RNA knockdown of STAT1. Using a new, openended approach to detect long-distance interactions, we find that in human vascular endothelial cells the enhancer interval containing the CAD locus physically interacts with the CDKN2A/B locus, the MTAP gene and an interval downstream of IFNA21. In human vascular endothelial cells, interferon-c activation strongly affects the structure of the chromatin and the transcriptional regulation in the 9p21 locus, including STAT1-binding, long-range enhancer interactions and altered expression of neighbouring genes. Our findings establish a link between CAD genetic susceptibility and the response to inflammatory signalling in a vascular cell type and thus demonstrate the utility of genome-wide association study findings in directing studies to novel genomic loci and biological processes important for disease aetiology.
Genome-wide association studies (GWAS) have identified eight SNPs in the 9p21 interval strongly associated with CAD 1-4 and other vascular diseases 11, 12 , all of which are highly correlated (r 2 . 0.8) and located in a 53-kb linkage disequilibrium block. The haplotype diversity in this interval is limited in Caucasians with ,25% of individuals homozygous for the risk haplotype that confers a ,2 fold greater risk of myocardial infarction than noncarriers 2 . Independent studies have identified four more SNPs associated with type 2 diabetes (T2D) in an adjacent but distinct 11-kb linkage disequilibrium block [5] [6] [7] . The associated CAD and T2D SNPs (Supplementary Table 1 ) lie in a gene desert ( Fig. 1 ) flanked by CDKN2B (130 kb upstream) and DMRTA1 (370 kb downstream), indicating that the functional variants underlying the association are probably in regulatory elements. The CAD interval overlaps with the 39 end of a non-coding gene with unknown function, CDKN2BAS, which is co-expressed with the CDKN2A/B locus 13 . In this study we used a multi-pronged approach involving cellular assays and population sequencing to identify and functionally characterize the variants underlying the 9p21 association with CAD ( Supplementary Fig. 1 ). We initially sought to identify regulatory elements in the 9p21 gene desert by examining transcription factor binding and chromatin modification profiles in human cells including HeLa, K562 and human embryonic stem cells 14 . Histone H3 trimethylated at lysine 4 (H3K4me3) is associated with promoters of active genes, and by looking for this mark we determined that the CDKN2B and DMRTA1 promoters were the only ones in the interval (Fig. 1) . CTCF-binding sites mark insulators 15 ; by analysing data of this factor in HeLa cells, we identified seven potential insulators in the 9p21 interval. One insulator is located close to the CDKN2B promoter and another one is located 130 kb upstream, in the CAD interval. Lastly, we searched for marks indicative of enhancers; enrichment of histone H3 monomethylation at lysine 4 (H3K4me1), binding of p300 and MED1, presence of DNase hypersensitivity sites (DHS) and depletion of H3K4me3 16 . Looking at these marks, we predict the locations of 33 enhancers, of which 26 are significantly enriched in conserved sequences (P , 0.01; Supplementary Table 2) . Six enhancers are proximal to the CAD interval; nine enhancers are located in the CAD interval (referred to as ECAD1-9), two in the T2D interval (referred to as ET2D1-2) and 16 distal to the T2D interval. The majority of the 33 predicted enhancers fall in the proximal part of the gene desert, in or near the CAD and T2D intervals. These findings were further supported by the analysis of publicly available genome-wide data sets generated to predict regulatory elements using a variety of cell types (Fig. 1) . Additionally, we validated the enhancer activity of the ECAD2, ECAD4, ECAD5, ECAD7, ECAD8, ECAD9 and ET2D1 elements using luciferase reporter assays in HeLa cells (data not shown). Interestingly, we determined that the 9p21 interval is the second densest gene desert for predicted enhancers (7.5 per 100 kb) in the human genome and the one containing the most disease-associated variants (10 SNPs; Supplementary Table 3 ). These data indicate that the 9p21 gene desert has an important regulatory function.
To identify the complete set of DNA variants in the 9p21 gene desert we sequenced a 196-kb interval (from the CDKN2B promoter to 65 kb distal to the T2D interval) in 50 individuals of European descent and used the variants to refine the pattern of linkage disequilibrium in the interval (Fig. 2a) . We identified 765 variants (31 insertions and/or deletions (indels) and 734 SNPs) and used the r 2 correlation coefficient to identify variants in linkage disequilibrium with any of the 8 CAD-or 4 T2D-associated SNPs. Of the 765 variants, 41 spanning 44 kb are in perfect linkage disequilibrium with a CAD-associated SNP, increasing to 131 variants spanning 111 kb when lowering the r 2 threshold to 0.5 (Fig. 2b) . In contrast to the CAD interval, only 23 variants were in linkage disequilibrium (r 2 $ 0.5) with at least one of the 4 T2D-associated SNPs, spanning 11 kb. No variants were in linkage disequilibrium (r 2 $ 0.5) with both CAD-and T2D-associated SNPs.
The functional variants underlying the association of 9p21 with CAD and T2D are highly likely to be a subset of the 131 and 23 candidate variants in linkage disequilibrium (r 2 $ 0.5) with the initial CAD-or T2D-associated SNPs, respectively. However, the strong linkage disequilibrium structure in the 9p21 gene desert presents a hurdle for the precise identification of the causative functional variants using only genetic evidence. Thus, we determined which of the candidate variants are located in functional elements. Five of the CAD candidate variants are located in exons and 118 in introns of CDKN2BAS; however, none of the exonic variants are located in a conserved element, indicating that they are unlikely to be functional. Thirty-three CAD candidate variants are located in ECAD1-9 sequences; ECAD9 is significantly enriched for variants (11 in 1,700 bp; P , 3.1 3 10
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). The remaining 22 variants are distributed in ECAD1 (3 variants), ECAD2 (2), ECAD3 (8), ECAD4 (1), ECAD5 (3), ECAD6 (1), ECAD7 (3) and ECAD8 (1). Six of the 23 T2D candidate variants are located in a T2D enhancer, 5 of which are in ET2D1 and 1 in ET2D2.
To identify candidate regulatory variants, we computationally determined which variants disrupt consensus transcription-factor-binding sites in the predicted enhancers (Supplementary Tables 4 and 5 ). Although many of the enhancers in the CAD interval had variants disrupting transcription-factor-binding sites, ECAD9-containing eight such variants-was the most notable. Additionally, the SNP (rs10757278) most consistently associated with increased risk of CAD 17 is in ECAD9 and disrupts a transcription-factor-biding site involved in the inflammatory response (STAT1; Supplementary Table 4 ). The rs10811656 and rs10757278 SNPs are located 4-bp apart in the predicted ECAD9 STAT1-binding site in the non-risk haplotype, which is disrupted in the risk haplotype (TTCCGGTAA . TTCTGGTAG). STAT1 has previously been shown to bind this locus in HeLa cells 18 , which are heterozygous for rs10811656/rs10757278 alleles, when treated with interferon-c (IFN-c) . We observed the binding of STAT1 at the same locus in human vascular endothelial cells (HUVECs) heterozygous for the rs10811656/rs10757278 alleles on treatment with IFN-c (Fig. 3a) . We examined the effect of IFN-c treatment in heterozygous HeLa and HUVEC cells on the expression of CDKN2B and CDKN2BAS. Interestingly, we noticed that IFN-c treatment leads to the repression and induction of CDKN2B and CDKN2BAS, respectively. This effect is greater in HUVECs, where CDKN2BAS expression is induced fourfold and CDKN2B transcription is repressed twofold (Fig. 3b) . These results are consistent with the epigenetic transcriptional repression of CDKN2B induced by ANRIL, the transcript encoded by CDKN2BAS
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.
To validate the disruption of STAT1 occupancy at the rs10811656/ rs10757278 risk alleles, we used lymphoblastoid cells lines (LCLs) homozygous for the CAD risk haplotype. STAT1 is constitutively expressed at high levels in LCLs 20 . We showed by ChIP that STAT1 binds at ECAD9 in two LCLs homozygous for the CAD non-risk haplotype (2.7-fold enrichment), whereas it does not bind in two LCLs homozygous for the risk haplotype (Fig. 3c) . To establish further a functional link between STAT1 occupancy in ECAD9 and expression of CDKN2BAS, we assessed the expression of CDKN2BAS in LCLs on STAT1 short interfering RNA (siRNA)-mediated knockdown; the expression of CDKN2BAS was significantly up-regulated (sevenfold) in LCLs homozygous for the CAD non-risk haplotype, but the effect was quite small in LCLs homozygous for the CAD risk haplotype (Fig. 3d) . These results are consistent with the fact that STAT1 fails to bind ECAD9 in the CAD risk haplotype and thus is unlikely to participate in CDKN2BAS regulation. Interestingly, these results indicate that the effects of STAT1 binding at ECAD9 may have cell-typespecific differences on the expression of CDKN2BAS between LCLs (repression) and HUVECs (activation) (Supplementary Discussion).
To determine which genes are interacting with and potentially regulated by the ECAD9 enhancers we examined all genes (20 upstream 29 and STAT1 in IFN-ctreated and untreated HeLa cells (track D3) 18 as well as the distribution of 9p21 chromatin marks in the ENCODE data 30 (tracks E1 and E2; Supplementary Methods) are indicated. Ctrl, control.
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and 1 downstream) located within 2 Mb for interactions. As longrange enhancer interactions are often tissue specific 21 we chose to use HUVEC cells as a model system for vascular endothelium. We performed chromatin conformation capture (3C) using cross-linked HUVECs grown in standard conditions, followed by BamH1 digestion of the chromatin and diluted re-ligation 22 . We analysed the 3C using a novel approach derived from combining 3C with DNA selection and ligation 23 (method referred to as 3D-DSL) and examined the sequences flanking the ligated acceptor and donor BamH1 sites using highthroughput sequencing. The resolution of 3D-DSL is limited by the distribution of BamH1 sites, and to compensate for this we selected 6 BamH1 sites flanking ECAD9 and other neighbouring enhancers as acceptor sites, and 145 BamH1 donor sites distributed throughout the 2 Mb of sequence tested for interactions. We identified nine donor sites interacting strongly with the enhancer acceptor sites (Fig. 4a) , of which seven are sufficiently distant (.45 kb) from the acceptor sites to be recognized as specific (Supplementary Table 6 ). They occur in four areas: (1) the CDKN2A/B locus; (2) the MTAP gene; (3) downstream of IFNA21; and (4) downstream of the T2D-associated region (DOTAR), an interval of unknown function. Accounting for the resolution limitations due to the distribution of BamH1 sites, we did not assign ligated acceptor sites as belonging to ECAD9 but rather refer to them as 'associated enhancers' and grouped the donor site interactions in CDKN2A and CDKN2B as 'CDKN2A/B'. We confirmed the interactions between the associated enhancers and surrounding genes identified by the 3D-DSL approach using traditional methods. The interaction between the associated enhancers and IFNA21, which spans 946 kb, was assayed by fluorescence in situ hybridization (FISH). We examined whether or not treatment with IFN-c would affect this long-range interaction and observed that the enhancers and IFNA21 are in close proximity in 58% versus 37% of the chromosomes analysed in HUVEC nuclei in the presence and absence of IFN-c, respectively (P , 1.63 3 10 Table 7 ). These data indicate that this interaction occurs basally, but is significantly remodelled on treatment with IFN-c. We validated more closely interacting loci via site-specific polymerase chain reaction (PCR) on the religated 3C DNA and verified that the interaction between the associated enhancers and the CDKN2A/B locus is strengthened in the presence of IFN-c whereas the interaction with MTAP is reduced (Fig. 4b) .
Our study shows that IFN-c stimulation and STAT1 binding at ECAD9 have important roles in regulating the expression of CDKN2B and CDKN2BAS. Our findings are consistent with previous studies observing a correlation between CAD risk variants and CDKN2A/B expression in lymphocytes 10 , and reduced expression of CDKN2A/B in cardiac and other tissues in a mouse model with the orthologous CAD interval deleted 8 . We demonstrate also that the associated enhancers physically interact with the intervals encoding CDKN2A/B, MTAP and IFNA21 in HUVECs and that these interactions are remodelled on IFN-c treatment, thus indicating that the STAT1-binding site in ECAD9 is a key regulatory sequence. STAT1 is a downstream effector of the pathway that mediates response to inflammation, which is associated with angiogenesis 24 and atherosclerosis pathogenesis 25 in endothelial tissue. Thus, in endothelial tissues, the biological effects of the rs10811656 and rs10757278 risk alleles disrupting the ECAD9 STAT1-binding site might be augmented during activation of the inflammatory 
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response. It is likely that the unique enhancer landscape of 9p21 is governed by higher-order chromatin structure and thus involved in different temporal-or tissue-specific expressions of additional genes than those identified in our study 26 . Future studies assessing the effects of variants on the 9p21 chromatin landscape under different physiological conditions and cells types will undoubtedly provide further insights into the association of this interval with CAD and T2D susceptibility.
METHODS SUMMARY
HUVECs, LCLs and IFN-c treatment. The two HUVEC cell lines used in the study were derived from male Caucasian donors genotyped as heterozygotes for the 9p21 CAD-associated SNPs. The four Epstein-Barr virus (EBV)-transformed LCLs were selected for their genotypes (two homozygous CAD risk or two homozygous CAD non-risk) using the HapMap data 27 . Experiments were performed within 2-4 passages by treating cells with 100ngml
21 of IFN-c (R&D) for 24 h. Treated and untreated cells were subjected to PCR with reverse transcription (RT-PCR) (HUVECs), ChIP (HUVECs and LCLs), 3C analysis (HUVECs) or FISH (HUVECs). Direct DSL and sequencing of 3C interactions. For probe design, we designed 12 acceptor probes in the interval chr9:22100523-22126469 (hg18; spanning from ECAD7 to the ET2D2 enhancer), on both strands immediately 39 of the six BamHI sites in the region. We designed 290 donor probes on both strands immediately 59 of the 145 BamHI sites in the interval chr9:21035934-22494089 (hg18; except where acceptor probes were designed). A universal sequence added to the probes is compatible with Illumina GA adapters for direct sequencing. The 12 acceptor probes and 290 donor probes (Supplementary Table 8 ) were pooled in equimolar amounts, separately.
For 3D-DSL sequencing, the DSL ligation products were prepared as described previously 23 . 3C was performed as per ref. 28 and the products were sheared by sonication. The sheared DNA (200-600 bp) was purified and biotinylated. Donor and acceptor probes pools were annealed to the biotinylated 3C samples and the biotinylated DNA was bound on to streptavidin magnetic beads. The 59 phosphate of acceptor probes and 39 OH 2 of donor probes were ligated using Taq DNA ligase. The ligated products were washed and eluted from the streptavidin 
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METHODS
Annotation of the 9p21 gene desert. The two protein coding genes CDKN2B and DMRTA1 flank the 9p21 gene desert. The CAD and T2D intervals (Fig. 2a) 32, 33 , CDKN2BAS lacks strong sequence conservation across its transcribed region but does contain some short strongly conserved elements that are probably the functional domains in the gene. Its transcriptional start site is ,300 bp from the CDKN2A promoter on the anti-sense strand, indicating a possible regulatory role 34 . Sequenced samples. Two-hundred and forty-four self-reported Caucasian males enrolled in the Scripps Translational Science Institute (http://www.stsiweb.org/) GeneHeart cohort were genotyped at ten SNPs (Supplementary Table 1 ) on the Sequenom MassARRAY platform according to the manufacturer's instructions. The eight CAD Sequenom genotypes (Supplementary Table 9 ) or four T2D genotypes derived from the sequence data were phased in haplotypes using the program PHASE 2.1.1 35 . For deep sequencing of the 9p21 interval we selected 25 samples homozygous for the CAD risk haplotype (22 H1/H1 and 3 H1/H5), 24 samples homozygous for the CAD non-risk haplotype (15 H2/H2, 7 H2/H3, 1 H3/H3, 1 H2/H6), and 1 sample with a non-risk and a mixed haplotype (1 H2/H17) (Supplementary Table 10 ). Our selection of the 50 samples for sequencing considered some of the haplotype diversity in the population, without impairing our ability to assign newly identified variants to either the CAD risk or non-risk haplotypes. The sequencing method is described as Supplementary Information. T2D-and CAD-associated variants. Using the Caucasian HapMap (version 24) genotypes, we identified 13 and 44 variants in linkage disequilibrium at an r 2 $ 0.5 with any of the initial four T2D variants (rs7020996, rs2383208, rs10811661, rs10757283) or the initial eight CAD variants (Supplementary Tables 1, 4 and 5) respectively. Using the sequence data, we identified 20 and 131 variants in linkage disequilibrium at an r 2 $ 0.5 with any of the initial three T2D variants (rs2383208, rs10811661, rs10757283) and eight initial CAD variants, respectively. One of the initial associated T2D SNPs (rs7020996) is located in a long-range PCR primer site that was part of the set of primers used to amplify the 196-kb interval and was thus filtered out in our initial analysis. Using the union of the two data sets (HapMap and sequencing), we identify a total of 23 and 131 variants in linkage disequilibrium at an r 2 $ 0.5 with any of the four initial T2D variants and eight initial CAD variants, respectively, including the associated SNPs themselves (Fig. 2b) . ChIP-chip experiments. HeLa cells were obtained from ATCC. ChIP, DNA purification and ligation-mediated PCR were performed as described 16 using commercially available (anti-H3K27ac, Abcam ab4729; anti-H3K4me1, Abcam ab8895; anti-H3K4me3, Upstate 07-473; anti-p300, Santa Cruz sc-585; anti-MED1, Santa Cruz sc-5334) or previously described antibodies 15, 16 and the ChIP DNA was hybridized to tiling microarrays and to custom-made enhancer microarrays (NimbleGen Systems) as described 15, 16 . ChIP-chip targets for CTCF, p300 and MED1 were selected with the Mpeak program 36 . We used MA2C to normalize and call peaks on Nimblegen HD2 arrays 37 . Enhancers were predicted as previously described 38 . H3K4me3 is associated with promoters of active genes 16 , CTCF-binding sites mark insulators 39 . Marks indicative of enhancers are enrichment of H3K4me1, binding of p300 and MED1, presence of DNase hypersensitivity sites and depletion of H3K4me3. Enhancer density in gene deserts. We used the genomic coordinates (NCBI36) of the protein-coding genes 40 to identify gene-desert intervals longer than 400 kb in size. Using the coordinates of the predicted transcriptional enhancers in HeLa 14 we counted the number of enhancers per interval and inferred the expected number of enhancers based on size and assuming homogeneous distribution. We tested for heterogeneity using a chi-squared test to compare the whole genome distribution and corrected for the number of tests using the Bonferroni correction. The gene deserts were then filtered for a significant enrichment in predicted enhancers (corrected P value , 0.01) and ranked by decreasing enhancer density (Supplementary Table 3 ).
For each of the selected gene deserts, we identified and counted the SNPs in association with diseases using the public GWAS catalogue (October 2009) 41 . Using the method described earlier in the genome assembly hg18, we identified 1,155 gene deserts of which 129 were significantly enriched in predicted enhancer elements (corrected P value , 0.01). Fifty of those harbour SNPs associated with diseases 41 . The 9p21 interval is the second densest gene desert for predicted enhancers (7.5 per 100 kb) and the one containing the most disease-associated variants (10 SNPs) (Supplementary Table 3 ). The density of enhancers in the 9p21 interval is thus six times higher than the genome-wide density (1.2 enhancers per 100 kb; P , 6.54 3 10
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). Sequence conservation of enhancer elements. Conserved bases were defined as nucleotides with a conservation score $1.65 (95th percentile in the interval) in the multispecies sequence comparison track at UCSC (44 ways placental mammals PhyloP conservation score). Each 9p21 predicted enhancer was tested to determine if it was significantly enriched for conserved sequences as follows: the ratio of the number of conserved bases to the total predicted enhancer length was compared to that of non-enhancer sequences in the re-sequenced interval using a chi-squared test. Enhancers with a P value , 0.01 were considered to be significantly enriched for conserved sequences (Supplementary Table 2 ). Of note, the predicted enhancers have already been shown to be statistically more evolutionary conserved 14 . However, owing to the ,1-2-kb resolution of the enhancer prediction method, we manually adjusted the boundaries of the enhancers located in CAD and T2D intervals (Supplementary Table 2 ) to include adjacent conserved sequences. Identification of transcription-factor-binding sites. MotifLocator 42, 43 at a stringency of 0.01% was used to predict potential binding sites (transcriptionfactor-binding site models from the JASPAR and TRANSFAC databases) in the 60 bp of sequence upstream and downstream of each variant locus, both alleles were considered. We retained the transcription-factor-binding site predictions that were disrupted by one of the two alleles for all candidate variants in linkage disequilibrium (r 2 $ 0.5) with CAD or T2D variants (Supplementary Tables 4 and 5 ). Cell culture of HUVECs and LCLs and IFN-c treatment. The two HUVEC cell lines (Lonza) used in the study were from male Caucasian donors and genotyped as heterozygotes for the 9p21 CAD-associated SNPs using the method described for HeLa genotyping (see Supplementary Methods). The EBV-transformed LCLs (Coriell Institute) were selected for their genotypes using the HapMap data 28 : LCLs NA12156 and NA10839 were homozygous for the CAD risk haplotype, whereas LCLs NA12750 and NA10847 were homozygous for the non-risk haplotype. Experiments were performed within 2-4 passages by treating cells with 100 ng ml 21 of IFN-c (R&D) for 24 h then subjected to RT-PCR (HUVECs), ChIP (HUVECs and LCLs), 3C analysis (HUVECs) or FISH (HUVECs), as described later. ChIP. ChIP was performed essentially as described previously 44 . In brief, cells were crosslinked for 10 min and were then subjected to sonication using Bioruptor (Diagenode) to fragment the chromatin to obtain 200-1,000-bp fragments. Sonicated chromatin was precleared with a cocktail containing 50% protein A/G beads slurry (Pierce), salmon sperm DNA and bovine serum albumin (BSA). Precleared chromatin was incubated with anti-STAT1 antibody (IP sample; SantaCruz biotechnology) or with rabbit-IgG (Upstate Biotechnology; IP control). Protein A/G bead cocktail was then added to pull-down the antibody-bound chromatin and was subjected to elution using sodium biocarbonate buffer containing SDS and dithiothreitol (DTT). Eluted chromatin was de-crosslinked and proteins were removed by treating with proteinase K. The purified immunoprecipitated chromatin was subjected to PCR amplification of specific targets using oligonucleotides primers (Supplementary Table 11 ) along with input chromatin and mock IP (IgG) control. The level of enrichment was measured using quantitative PCR with Q-Master mix (Agilent) on real-time thermocycler MX3000P (Startagene). The quantity of target specific IP DNA was first normalized to the input (2
). The level of enrichment was then calculated by dividing by the normalized quantity from the mock IP control (IgG). The average of three replicates (Fig. 3a) or three measurements in two cell lines (Fig. 3c) is shown. The significance was assessed using a two-tailed Student's t-test. RT-PCR. RNA was isolated from IFN-c-treated and untreated HUVEC and LCL cells and 1 mg total RNA was reverse transcribed using SuperScript III Reverse Transcriptase(Invitrogen)aspermanufacturer'sinstructions.QuantitativePCRswere performed in MX3000P (Stratagene) using Q-PCRmaster mix (Agilent). For normalization, DCt values were calculated using the formula: DCt 5 (Ct target 2 Ct control ), where control corresponds to the level of GAPDH transcript. Fold differences in normalized gene expression were calculated by dividing the level of expression of the treated sample with the untreated sample (Fig. 3b) or between siSTAT1 and siControl transfected cells (Fig. 3d) . The result of three replicates (Fig. 3b) or three replicates in two cell lines (Fig. 3d) was averaged and the significance of changes was assessed using a two-tailed Student's t-test (Fig. 3d only) . siRNA analysis. Five million LCL cells either homozygous for the non-risk (NA12750 and NA10847) or for the risk (NA12156 and NA10839) CAD haplotype were electroporated with siSTAT1 (Ambion) and control siRNA (Ambion) using Amaxa Nucleofector I electroporator (AMAXA Biosystems). Cells were subjected to RT-PCR and ChIP analysis 24 h after electroporation as described earlier. The knockdown efficiency was verified by ChIP ( Supplementary Fig. 3 ) 3C. 3C was performed as described previously 29 . Briefly, 25 million cells were fixed by adding 1% formaldehyde at room temperature (22 uC) for 10 min. The reaction was stopped by adding glycine. Lysis buffer (500 ml of 10 mM Tris-HCl, pH 8.0, 10 mM NaCl, 0.2% Igepal CA630; protease inhibitors (Sigma)) was added and cells were incubated on ice. Next, cells were lysed with a Dounce homogenizer by moving the pestle up and down ten times, incubating on ice for one minute followed by ten more strokes with the pestle. The suspension was spun down at 5,000 r.p.m. at room temperature. The supernatant was discarded and the pellet was washed twice with 500 ml ice-cold 13 NEBuffer 3 (NEB). The pellet was then LETTER RESEARCH resuspended in 13 NEBuffer 3 and split into five 50-ml aliquots. Chromatin was subsequently digested overnight by adding 400 Units BamH1 (NEB). Each digested chromatin mixture was ligated by adding T4 DNA Ligase (800 U) in 20 times the initial volume for 4 h at 16 uC. One aliquot out of five was kept as an unligated control where ligase was omitted. After incubation at 16 uC, the chromatin was de-crosslinked overnight at 65 uC and purified twice with phenol and then with phenol:chloroform (25:24) . DNA was precipitated and pellets were airdried before resuspending in 25 ml 13 TE (10 mM Tris, 1 mM EDTA, pH 8). To degrade any carryover RNA, 1 ml RNase A (1 mg ml
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) was added to each tube and incubated at 37 uC for 15 min. Chromatin was used for subsequent DSL analysis (see below) or for validation PCR (primers are listed in Supplementary Table 11) . DSL and sequencing of 3C interactions. For probe design, we designed 12 acceptor probes in the interval chr9:22100523-22126469 (hg18; spanning from ECAD7 to the ET2D2 enhancer), on both strands immediately 39 of the six BamHI sites in the region. The acceptor probes are 59-pTCC-(locus)-CCTGTGGT CGTAGCATCAGC-39, where (locus) indicates a 17-nucleotide sequence immediately 39 of the BamH1 site and CCTGTGGTCGTAGCATCAGC is the complimentary sequence to the adaptor (Primer B-AD in Supplementary Table 11 ). We designed 290 donor probes on both strands immediately 59 of the 145 BamHI site in the interval chr9:21035934-22494089 (hg18; except where acceptor probes were designed). The probes sequences are shown in Supplementary Table 8 . The donor probes are 59-AATGATACGGCGACCACCGAGAT-(locus)-GGA-39, where (locus) indicates the 17-nucleotide sequences immediately 59 of the BamH1 site. The uniqueness of the (locus) oligonucleotides was verified with BLAST and BOWTIE alignment. The universal sequences above are adapted for the Illumina GA adapters and compatible with flow-cell bridge amplification. The 12 acceptor probes and 290 donor probes were pooled in equimolar amounts, separately.
For 3D-DSL sequencing, the DSL ligation products were prepared as described previously 23 . The 3C products from HUVEC cells were sheared by sonication. The sheared DNA (200-600 bp) was purified from gel and subjected to biotinylation before precipitation with 100% ethanol. Donor and acceptor probe pools (final 2.5 fmol each probe) were annealed to the biotinylated 3C samples at 45 uC for 2 h followed by 10 min at 95 uC. Unbound oligonucleotides were removed by washes while biotinylated DNA was bound on to streptavidin magnetic beads. The 59-phosphate of acceptor probes and 39-OH of donor probes were ligated using Taq DNA ligase at 45 uC for 1 h. These ligated products were washed and eluted from beads and then amplified by PCR using primers A and B-AD (or Primer B-BC1 and -BC2 if bar coding was used; see Supplementary Table 11) for deep sequencing on the Illumina GA2 using Primer A as sequencing primer.
For 3D-DSL analysis, we first built a virtual library of the 3,480 possible donoracceptor sequences by in silico concatenating all 12 acceptor sequences with 290 donor sequences. Because the religation products span a BamH1 restriction site, we first selected sequence reads containing intervening GGATCC sequence (BamH1), aligned these reads to the virtual library of DSL donor-acceptor sequences using BOWTIE 45 allowing for no mismatches, and then counted the number of reads mapped to every interaction. The summary results of these steps are presented in Supplementary Table 12 . The fraction of total reads mapped per donor site is presented in Supplementary Table 6 . Although the most highly covered donor sites are consistent between the technical replicate samples, we observed some variability. Except for some low covered potential false-positive interactions, we think that the variability could be due to the stochastic nature of the long-range chromatin interactions and of the 3C assay itself. To strengthen our confidence in the results we averaged the two experiments and focused our study on donor sites covered by more than 1% of the reads on average over the two experiments (highlighted in bold in Supplementary Table 6 ). We realize that this is an empirical threshold and that some of the interactions below this threshold will also probably be real. Because of the low resolution and the stochastic nature of the 3D-DSL, constrained by the distribution of BamH1 sites, we did not distinguish between sites located within 50 kb of each other (for example, grouping interactions in CDKN2A and CDKN2B as 'CDKN2A/B' or ECAD7-9 and ET2D1-2 as 'associated enhancers').
For 3D-DSL validation by PCR, to validate the interactions between the enhancer interval and the CDKN2A/B and MTAP loci (Fig. 4b) , we performed PCR on the 3C ligation product. We designed two sets of primer pairs (Supplementary Table 11): (1) between a BamH1 donor site close to CDKN2A/B (hg18, chr9:21985877-21985882) and a BamH1 acceptor site located in ECAD8 (hg18; chr9:22108031-22108036); (2) between a BamH1 donor site in the MTAP gene (hg18; chr9:21831910-21831915) and a BamH1 acceptor site located in ET2D2 (hg18; chr9:22126466-22126471). These experiments were all performed in replicate with the same effects observed. The identified long-range interaction between the CDKN2A/B locus and the associated enhancers in untreated HUVECs was observed consistently by 3D-DSL, but not clearly identified by traditional, PCRbased 3C. This indicates that the 3D-DSL is a more sensitive method for the detection of long-range interactions. The interacting donor sites located in very close proximity to the associated enhancers cannot be resolved using 3C and were not assayed nor were the interactions with DOTAR because of the inability to design primers due to low GC content. FISH. HUVEC cells were grown on polylysine-coated cover slips and treated with or without IFN-c (100 ng ml
) for 24 h. Cells were fixed with freshly made 4% paraformaldehyde/PBS at room temperature and permeabilized with 0.5% Triton X-100. Freeze/thaw cells in liquid N 2 , 20 s 3 5 times and incubated in 0.1 N HCl for 5 min. To further permeabilize the cells, they were treated with 0.01 N HCl/ 0.002% pepsin for 3 min 40 s, stopped by 50 mM MgCl 2 /PBS and equilibrated in 50% formamide/23 SSC for 2 h before hybridization. Two microlitres each of the two labelled BAC probes (Empire Genomics) were mixed with 7 ml of hybridization buffer (Empire genomics). The slides were placed face down on the hybridization mix, sealed with fixogum and air-dried. After denaturation at 76 uC for 3 min, the slides were transferred to a prewarmed dark wet box at 37 uC and hybridized overnight. The slides were then washed 3 times with 50% formamide/23 SSC/0.1% Tween 20 at 37 uC; 3 times with 0.13 SSC/0.1% Tween 20 at 60 uC; 2 times with 23 SSC, once at 60 uC and once at room temperature; rinsed with 13 PBS twice at room temperature. The cells were then mounted on the slides with prolong gold-DAPI antifade mounting reagent (Invitrogen), and analysed under fluorescent microscope counting at least 100 cells for each experiment. The experiments were done on three biological replicates. The probes used spanned the enhancer region (hg18; chr9:22100296-22249612; RP11-248B1 labelled with fluorescein; Empire Genomics) and the IFNA21 region (chr9:20996400-21158464; 942 kb away from the enhancer; RP11-113D19, labelled with 5-ROX; Empire Genomics). For each experiment, we counted the number of cells with biallelic, monoallelic or negative interactions. We then performed a chi-squared test for goodness of fit using these three values comparing between IFN-c treated and untreated. We found that 58% of the chromosomes in 315 HUVEC nuclei analysed (heterozygous for the CAD risk and non-risk haplotypes) showed an overlapping signal from the two probes ( Supplementary Fig. 2 ) when the cells were treated with IFN-c, in contrast with 37% of overlapping chromosomes in the absence of IFN-c treatment. These data indicate that this interaction occurs basally, but is significantly remodelled on treatment with IFN-c (P , 1.63 3 10 225 ) (Supplementary Table 7 ).
